Jefferies initiated coverage of Inhibikase Therapeutics (IKT) with a Buy rating and $8 price target The stock looks inexpensive as its novel imatinib oral pro-drug IkT-001Pro will enter Phase 2B for PAH, with an added free Parkinson’s call option for oral risvodetinib, where expectations are super low, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKT:
- Inhibikase Therapeutics Secures Funding and Strengthens Leadership
- Inhibikase Therapeutics closes up to $275M financing, advances IkT-001Pro
- Inhibikase Therapeutics price target lowered to $5 from $15 at H.C. Wainwright
- Inhibikase Therapeutics Secures $110M for Drug Development
- Inhibikase Therapeutics prices 58.3M shares at $1.37 in private placement